Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome

• US 5,437,861 A
• Filed: 03/16/1993
• Issued: 08/01/1995
• Est. Priority Date: 03/16/1993
• Status: Expired due to Fees

• Current Assignee: Rhone-Poulenc Rorer Pharmaceuticals Incorporated (Sanofi )
• Original Assignee: Applied Immune Sciences, Inc. (Sanofi )
• Inventors: Blankenship, John, Okarma, Thomas B., Elkalay, Mohammad A., Lin, Abraham T.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Kulkosky, Peter F.
• Application Number:
  US08/032,357
• Time in Patent Office: 868 Days
• Field of Search: 424/724, 424/78.08, 530/811, 422/48
• US Class Current: 424/78.08
• CPC Class Codes: A61M 1/3431 upstream of the filter
• CPC Class Codes: A61M 1/3621 Extra-corporeal blood circuits single-needle circuits A61M1/30
• CPC Class Codes: A61M 1/3643 Priming, rinsing before or after use
• CPC Class Codes: A61M 1/3644 Mode of operation
• CPC Class Codes: A61M 1/3672 Means preventing coagulation
• CPC Class Codes: A61M 1/3673 Anticoagulant coating, e.g. Heparin coating
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: Y10S 530/811 Peptides or proteins is immobilized on, or in, an inorganic carrier

Abstract

This invention provides a composition, device and method for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient'"'"'s whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood.

Claims

1. A composition of matter comprising amorphous, particulate, non-spherical silica and a silica pretreating agent wherein the silica pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area between 150 m² /g and 600 m² /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin;

and wherein the composition is capable of removing selected factors from blood.

2. The composition of claim 1 wherein the specific surface area of the silica is between 150 m² /g and 1000 m² /g.

3. The composition of claim 2, wherein the specific surface area of the silica is between 200 m² /g and 600 m² /g.

4. The composition of claim 1 wherein the porosity of the silica is between 0.8 cc/g and 1.5 cc/g.

5. The composition of claim 1 wherein the silica is substantially unmodified chemically.

6. The composition of claim 1 in which the silica particles have a mean diameter less than about 1 mm.

7. The composition of claim 1 in which the silica particles have a mean diameter between about 50 and 250 microns.

8. The composition of claim 1 in which the silica has a mean pore diameter of about 30 Å

to 300 Å

.

9. The composition of claim 8 in which the silica has a mean pore diameter of about 60 Å

to 200 Å

.

10. The composition of claim 1 in which the human serum albumin comprises between 1% and 25% by weight of the silica pretreating agent.

11. The composition of claim 10 in which the human serum albumin comprises between 2.5% and 5% of the silica pretreating agent.

12. The composition of claim 1 in which the selected factors comprise cytokines, complement molecules, serotonin, histamine, cholesterol molecules, or angiogenesis factor.

13. The composition of claim 1, wherein the composition is comprised within a porous solid matrix, and wherein the composition is substantially devoid of covalent attachment to the matrix.

14. The composition of claim 1 contained within an article, the article comprising a means for retaining the composition.